Class-switzched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis
Data(s) |
2009
|
---|---|
Resumo |
Introduction Reconstitution of peripheral blood (PB) B cells after therapeutic depletion with the chimeric anti-CD20 antibody rituximab (RTX) mimics lymphatic ontogeny. In this situation, the repletion kinetics and migratory properties of distinct developmental B-cell stages and their correlation to disease activity might facilitate our understanding of innate and adaptive B-cell functions in rheumatoid arthritis (RA). Methods Thirty-five 'RTX-naïve' RA patients with active arthritis were treated after failure of tumour necrosis factor blockade in an open-label study with two infusions of 1,000 mg RTX. Prednisone dose was tapered according to clinical improvement from a median of 10 mg at baseline to 5 mg at 9 and 12 months. Conventional disease-modifying antirheumatic drugs were kept stable. Subsets of CD19+ B cells were assessed by flow cytometry according to their IgD and CD27 surface expression. Their absolute number and relative frequency in PB were followed every 3 months and were determined in parallel in synovial tissue (n = 3) or synovial fluid (n = 3) in the case of florid arthritis. Results Six of 35 patients fulfilled the European League Against Rheumatism criteria for moderate clinical response, and 19 others for good clinical response. All PB B-cell fractions decreased significantly in number (P < 0.001) after the first infusion. Disease activity developed independently of the total B-cell number. B-cell repopulation was dominated in quantity by CD27-IgD+ 'naïve' B cells. The low number of CD27+IgD- class-switched memory B cells (MemB) in the blood, together with sustained reduction of rheumatoid factor serum concentrations, correlated with good clinical response. Class-switched MemB were found accumulated in flaring joints. Conclusions The present data support the hypothesis that control of adaptive immune processes involving germinal centre-derived, antigen, and T-cell-dependently matured B cells is essential for successful RTX treatment. |
Formato |
application/pdf |
Identificador |
http://boris.unibe.ch/32327/1/4.pdf Möller, B; Aeberli, D; Eggli, S; Fuhrer, M; Vajtai, I; Vöglin, E; Ziswiler, HR; Dahinden, CA; Villiger, PM (2009). Class-switzched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis research & therapy, 11(3), R62. London: BioMed Central 10.1186/ar2686 <http://dx.doi.org/10.1186/ar2686> doi:10.7892/boris.32327 info:doi:10.1186/ar2686 info:pmid:19419560 urn:issn:1478-6354 |
Idioma(s) |
eng |
Publicador |
BioMed Central |
Relação |
http://boris.unibe.ch/32327/ |
Direitos |
info:eu-repo/semantics/openAccess |
Fonte |
Möller, B; Aeberli, D; Eggli, S; Fuhrer, M; Vajtai, I; Vöglin, E; Ziswiler, HR; Dahinden, CA; Villiger, PM (2009). Class-switzched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis research & therapy, 11(3), R62. London: BioMed Central 10.1186/ar2686 <http://dx.doi.org/10.1186/ar2686> |
Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion PeerReviewed |